Alzheimers Research & Therapy

Article	Citations
Structural brain improvements following individually tailored serious exergame-based training in mild neurocognitive disorders: exploratory randomized controlled trial	239
A novel electric field approach for improving cognitive function through ameliorating cell-specific pathology in P301S tauopathy mice	229
Serum phosphorylated tau protein 181 and neurofilament light chain in cognitively impaired heart failure patients	171
Prominent tauopathy and intracellular β-amyloid accumulation triggered by genetic deletion of cathepsin D: implications for Alzheimer disease pathogenesis	157
Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid Angiopathy	156
Association between antemortem plasma and structural MRI biomarkers and postmortem tau pathology in the Mayo Clinic Study of Aging	155
A biomarker-validated time scale in years of disease progression has identified early- and late-onset subgroups in sporadic Alzheimer’s disease	134
Linking eye movements, pupil responses, and brain networks in early cognitive decline	122
Associations of adherence to a healthy sleep pattern with the dementia risk in the UK biobank	121
Issues and recommendations for the residual approach to quantifying cognitive resilience and reserve	117
Moderating role of executive function in the relationship between specific white matter changes and long-term delayed recall in aMCI patients	116
Recent molecular insights and biosensor-based diagnostic technologies for hyperphosphorylated Tau in Alzheimer's disease	106
Correction: 18F-FDG PET can effectively rule out conversion to dementia and the presence of CSF biomarker of neurodegeneration: a real-world data analysis	103
Effect of the ABCA1 agonist CS-6253 on amyloid-β and lipoprotein metabolism in cynomolgus monkeys	97
Investigating the Aβ and tau pathology in autosomal dominant Alzheimer’s disease: insights from hybrid PET/MRI and network mapping	93
Anti-tau VHH therapy against PHF6: a safe approach to slowing the phenotype of tau pathology	90
Diagnostic performance of verbal fluency measures: a cross-sectional study in the stages of cognitive continuum	90
Development of a Japanese polygenic risk score model for amyloid-β PET imaging in Alzheimer’s disease	90
Comparing a pre-defined versus deep learning approach for extracting brain atrophy patterns to predict cognitive decline due to Alzheimer’s disease in patients with mild cognitive symptoms	85
Genetic and clinical landscape of Chinese frontotemporal dementia: dominance of TBK1 and OPTN mutations	83
An association of CSF apolipoprotein E glycosylation and amyloid-beta 42 in individuals who carry the APOE4 allele	83
Automated high-throughput quantification of plasma p-tau217 and APOE-ε4 for Alzheimer’s disease diagnosis and cognitive decline in a memory cohort	81
Impact of gender on the willingness to participate in clinical trials and undergo related procedures in individuals from an Alzheimer’s prevention research cohort	81
High-affinity antibodies specific to the core region of the tau protein exhibit diagnostic and therapeutic potential for Alzheimer’s disease	75
Greater baseline cortical atrophy in the dorsal attention network predicts faster clinical decline in Posterior Cortical Atrophy	71

ISX9 activates the Wnt/β-catenin signaling pathway and exerts neuroprotective effects in Alzheimer’s disease	71
Association of modifiable risk factors with progression to dementia in relation to amyloid and tau pathology	71
Granulovacuolar degeneration bodies are independently induced by tau and α-synuclein pathology	66
Stress-induced alteration of small extracellular vesicles drives amyloid-beta sequestration and exacerbates Alzheimer’s disease pathogenesis	66
Amyloid-β PET scans, economic strain and financial decision-making among persons with cognitive impairment and care partners: a mixed-methods analysis of the CARE-IDEAS study	64
Global and domain-specific cognitive intraindividual variability associations with neurodegenerative diagnoses and postmortem pathologies	62
The economic burden of subjective cognitive decline, mild cognitive impairment and Alzheimer's dementia: excess costs and associated clinical and risk factors	62
Longitudinal evaluation of common and unique brain-networks in variants of primary progressive aphasia	60
Cornuside alleviates cognitive impairments induced by Aβ1−42 through attenuating NLRP3-mediated neurotoxicity by promoting mitophagy	59
Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a Mendelian randomization analysis	59
A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects wi	58
Linking oxysterols and different stages of mild cognitive impairment: insights from gut metabolites and N6-methyladenosine	57
Near-infrared light reduces β-amyloid-stimulated microglial toxicity and enhances survival of neurons: mechanisms of light therapy for Alzheimer’s disease	56
Fluid biomarkers for neurodegenerative diseases: a comprehensive update	54
A multiscale brain network model links Alzheimer’s disease-mediated neuronal hyperactivity to large-scale oscillatory slowing	53
Impact of effective connectivity within the Papez circuit on episodic memory: moderation by perivascular space function	52
Whole-brain modeling of the differential influences of amyloid-beta and tau in Alzheimer’s disease	51
CEST imaging combined with 1H-MRS reveal the neuroprotective effects of riluzole by improving neurotransmitter imbalances in Alzheimer’s disease mice	50
Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the AppNL−F/NL−F knock-in mouse model of Alzheimer’s disease	49
Reduced plasma TIA-1: bridging established pathology and novel biomarker potential	48
Real—world application of lecanemab in early—stage alzheimer's disease: a single—center prospective cohort analysis	47
Tau seeding activity in the cerebrospinal fluid of Alzheimer disease patients predicts short-term cognitive decline	46
Hormone therapy is associated with lower Alzheimer’s disease tau biomarkers in post-menopausal females -evidence from two independent cohorts	45
Health-related quality of life in subjective cognitive decline and mild cognitive impairment: a longitudinal cohort analysis	45
Digital Clock and Recall is superior to the Mini-Mental State Examination for the detection of mild cognitive impairment and mild dementia	45
Identification of methylation-regulated genes modulating microglial phagocytosis in hyperhomocysteinemia-exacerbated Alzheimer’s disease	44
Correction: Applicability of in vivo staging of regional amyloid burden in a cognitively normal cohort with subjective memory complaints: the INSIGHT-preAD study	43
Navigating the introduction of anti-amyloid therapy in Europe: a position statement by individual members of the EADC	42
Genome-wide association studies of Alzheimer’s disease and related disorders stratified by sex, onset age, and Apolipoprotein E genotype reveal novel risk loci in African Americans	42
Functional gradients of the medial parietal cortex in a healthy cohort with family history of sporadic Alzheimer’s disease	41
Higher levels of myelin are associated with higher resistance against tau pathology in Alzheimer’s disease	40
The age-specific comorbidity burden of mild cognitive impairment: a US claims database study	40
Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer’s disease patients	39
Palmitoylation of death receptor p75NTR contributes to Alzheimer’s disease progression by regulating APP trafficking and degradation	39
Ap1s1 reduction in the aging brain heightens neuronal vulnerability to amyloid-β and oxidative stress in Alzheimer’s pathogenesis	38
Analytical and clinical performance of eight Simoa® and Lumipulse® assays for automated measurement of plasma p-tau181 and p-tau217	38
The role of structural and functional parameters in designing pathology-specific tDCS protocols for primary progressive aphasia	38
Polygenic pathways shape white matter vulnerability to Alzheimer’s disease-related pathophysiological changes	38
Mapping the long-term delayed recall-based cortex-hippocampus network constrained by the structural and functional connectome: a case-control multimodal MRI study	38
The interrelationships of CSF sTREM2, AD pathology, minimal depressive symptoms, and cognition in non-demented adults	36
Autonomic and neurosensory disorders in dementia with lewy bodies: prevalence and neural basis in the AlphaLewyMA cohort	36
Plasma neuregulin 1 as a synaptic biomarker in Alzheimer’s disease: a discovery cohort study	36
Elevated Aβ aggregates in feces from Alzheimer’s disease patients: a proof-of-concept study	36
Characterization of preclinical Alzheimer’s disease model: spontaneous type 2 diabetic cynomolgus monkeys with systemic pro-inflammation, positive biomarkers and developing AD-like pathology	35
Disruption of electrophysiological rhythms and memory impairment in an Alzheimer’s transgenic rat model	35
Interpretable machine-learning prediction of PSEN1 missense variant pathogenicity based on multi-omics enrichment in six core Alzheimer’s disease genes	35
Early visual alterations in individuals at-risk of Alzheimer’s disease: a multidisciplinary approach	35
White matter hyperintensities are a prominent feature of autosomal dominant Alzheimer’s disease that emerge prior to dementia	35
Association between ATN profiles and mortality in a clinical cohort of patients with cognitive disorders	34
Readthrough isoform of aquaporin-4 (AQP4) as a therapeutic target for Alzheimer’s disease and other proteinopathies	34

International consensus for the assessment of social cognition in neurocognitive disorders: framework definition and clinical recommendations of the SIGNATURE initiative	34
Development of multivariable prediction models for institutionalization and mortality in the full spectrum of Alzheimer’s disease	34
Correction: Comparative evaluation of clinical and cerebrospinal fluid biomarker characteristics in rapidly and non‑rapidly progressive Alzheimer’s disease	34
Associations between different tau-PET patterns and longitudinal atrophy in the Alzheimer’s disease continuum: biological and methodological perspectives from disease heterogeneity	34
Subjective cognitive complaints and blood biomarkers of neurodegenerative diseases: a longitudinal cohort study	33
An improved immunoassay detects Aβ oligomers in human biofluids: their CSF levels rise with tau and phosphotau levels	33
Diffusion tensor imaging analysis along the perivascular space suggests impaired glymphatic clearance in Lewy body dementia subtypes	33
CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease	33
Quantification of identifying cognitive impairment using olfactory-stimulated functional near-infrared spectroscopy with machine learning: a post hoc analysis of a diagnostic trial and validation of a	33
Real-world diagnostic performance of blood-based biomarkers for Alzheimer’s disease: robust performance except after stroke and high charlson comorbidity index	33
Plasma trimethylamine N-oxide (TMAO): associations with cognition, neuroimaging, and dementia	33
Correction: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody	33
Sex-specific risk factors and clinical dementia outcomes for white matter hyperintensities in a large South Korean cohort	33
Generalizable MRI normative modelling to detect age-inappropriate neurodegeneration	33
Clinical and biological relevance of glial fibrillary acidic protein in Alzheimer’s disease	32
The identification and cognitive correlation of perfusion patterns measured with arterial spin labeling MRI in Alzheimer’s disease	32
Polypharmacy in people with dementia: a nationwide Danish study	32
Cross-cultural effects of reminiscence therapy on life satisfaction and autobiographical memory of older adults: a pilot study across Mexico and Spain	32
Perivascular space enlargement accelerates in ageing and Alzheimer’s disease pathology: evidence from a three-year longitudinal multicentre study	31
Long-term low-dose acetylsalicylic use shows protective potential for the development of both vascular dementia and Alzheimer’s disease in patients with coronary heart disease but not in other individ	31
Centiloid values from deep learning-based CT parcellation: a valid alternative to freesurfer	31
Head-to-head comparison of tau PET tracers [18F]PI-2620 and [18F]RO948 in non-demented individuals with brain amyloid deposition: the TAU-PET FACEHBI cohort	31
Dynamic network model reveals distinct tau spreading patterns in early- and late-onset Alzheimer disease	31
Choroid plexus volume as a novel candidate neuroimaging marker of the Alzheimer’s continuum	31
Divergent brain regional atrophy and associated fiber disruption in amnestic and non-amnestic MCI	31
Olfactory radiomics signatures link pTau217 to cognitive impairment in probable Alzheimer’s disease: a multi-cohort machine learning study	31
The autocrine motility factor receptor delays the pathological progression of Alzheimer’s disease via regulating the ubiquitination-mediated degradation of APP	31
18F-FDG PET can effectively rule out conversion to dementia and the presence of CSF biomarker of neurodegeneration: a real-world data analysis	30
Correction: Baseline structural MRI and plasma biomarkers predict longitudinal structural atrophy and cognitive decline in early Alzheimer’s disease	30
Associations of white matter hyperintensity regression and progression with cognitive and structural brain changes: a population-based cohort study	30
Detecting limbic predominant neurodegenerative co-pathologies in vivo in Alzheimer’s disease: magnetic resonance imaging markers, cognitive correlates, and prognosis	30
Accuracy of plasma Aβ40, Aβ42, and p-tau181 to detect CSF Alzheimer’s pathological changes in cognitively unimpaired subjects using the Lumipulse automated platform	30
Longitudinal characteristics of plasma biomarkers in Chinese older adults with Alzheimer’s disease	30
Alzheimer’s and neurodegenerative disease biomarkers in blood predict brain atrophy and cognitive decline	30
Dementia with Lewy bodies and gait neural basis: a cross-sectional study	30
Development and assessment of algorithms for predicting brain amyloid positivity in a population without dementia	30
Impact of dose and compliance of antidementia medications on long-term outcomes in Alzheimer’s disease: a nationwide real-world study	29
Genetic validation of ABI3 p.Ser209Phe variant and its effects on early brain pathology in asymptomatic elderly individuals	29
PACAP–Sirtuin3 alleviates cognitive impairment through autophagy in Alzheimer’s disease	29
Utility of 18F-Florzolotau PET as a prognostic and monitoring biomarker in a memory clinic cohort	29
Clusters of co-abundant proteins in the brain cortex associated with fronto-temporal lobar degeneration	29
Cognitive decline profiles associated with lewy pathology in the context of Alzheimer’s disease neuropathologic change	29
Predicting conversion of brain β-amyloid positivity in amyloid-negative individuals	29
Associations of resting heart rate with incident dementia, cognition, and brain structure: a prospective cohort study of UK biobank	29
A longitudinal study on quality of life along the spectrum of Alzheimer’s disease	29
Distinct effects of blood pressure parameters on Alzheimer’s and vascular markers in 1,952 Asian individuals without dementia	28
White matter hyperintensities and smaller cortical thickness are associated with neuropsychiatric symptoms in neurodegenerative and cerebrovascular diseases	28
Association of Alzheimer’s disease biomarkers with malnutrition and altered body composition in cognitively impaired patients: a cross-sectional memory clinic study	28
Different associations between amyloid-βeta 42, amyloid-βeta 40, and amyloid-βeta 42/40 with soluble phosphorylated-tau and disease burden in Alzheimer’s disease: a cerebrospinal fluid and fluorodeoxy	28
Evaluating the diagnostic performance of six plasma biomarkers for Alzheimer’s disease and other neurodegenerative dementias in a large Chinese cohort	28
Synaptic protein CSF levels relate to memory scores in individuals without dementia	28
Brain reserve contributes to distinguishing preclinical Alzheimer’s stages 1 and 2	28
Amyloid PET across the cognitive spectrum in former professional and college American football players: findings from the DIAGNOSE CTE Research Project	27
Multi-omics analyses identify gut microbiota-fecal metabolites-brain-cognition pathways in the Alzheimer’s disease continuum	27
Selective agonism of GPR34 stimulates microglial uptake and clearance of amyloid β fibrils	27
The reporting of neuropsychiatric symptoms in electronic health records of individuals with Alzheimer’s disease: a natural language processing study	27
Social frailty and its association with cognitive trajectories in older adults: a prospective cohort study	27
The associations of herpes simplex virus and varicella zoster virus infection with dementia: a nationwide retrospective cohort study	27
Clinical, neuroimaging, and biomarker profiling of four Alzheimer’s disease pedigrees caused by pathogenic APP variants	27
Rescue of protein dyshomeostasis in hippocampal astrocytes from an Alzheimer’s disease mouse model by stabilizing ER-mitochondrial interactions at a 20 nm distance	27
Italian adaptation of the Uniform Data Set Neuropsychological Test Battery (I-UDSNB 1.0): development and normative data	26
Nanoscale alterations in GABAB receptors and GIRK channel organization on the hippocampus of APP/PS1 mice	26
Potential role of Amyloid-β on the association between Orexin-A and blood-brain barrier leakage of globus pallidus in Alzheimer’s disease and dementia with lewy bodies	26
Letter to the Editor Authors’ Response: Choroid and choriocapillaris changes in early-stage Parkinson’s disease: a swept-source optical coherence tomography angiography-based cross-sectional study	26
Subclinical carotid artery atherosclerosis and cognitive function in older adults	26
evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disea	26
Longterm impact of disclosing amyloid PET results to individuals with subjective cognitive decline	26
How does apolipoprotein E genotype influence the relationship between physical activity and Alzheimer’s disease risk? A novel integrative model	25
Response to Xing et al.: post-marketing safety concerns with Lecanemab: a pharmacovigilance study based on the FDA adverse event reporting system database	25
β-Amyloid in blood neuronal-derived extracellular vesicles is elevated in cognitively normal adults at risk of Alzheimer’s disease and predicts cerebral amyloidosis	25
Quantitative estimate of cognitive resilience and its medical and genetic associations	25
Towards a national registry for Alzheimer’s disease and related dementias: rationale, design, and initial observations of the ABOARD cohort	25
Disruption of early visual processing in amyloid-positive healthy individuals and mild cognitive impairment	25
Cognitive impairment indicator for the neuropsychological test batteries in the Canadian Longitudinal Study on Aging: definition and evidence for validity	25
A longitudinal study of the 5xFAD mouse retina delineates Amyloid beta (Aβ)-mediated retinal pathology from age-related changes	25
Correction: Updated safety results from phase 3 lecanemab study in early Alzheimer’s disease	25
A new paradigm for stratified cognitive assessment: fusing serum Raman spectroscopy and ensemble learning	24
Influence of co-pathology on CSF and plasma synaptic markers SNAP25 and VAMP2 in Alzheimer’s disease and Parkinson’s disease	24
Longitudinal resting-state EEG in amyloid-positive patients along the Alzheimer’s disease continuum: considerations for clinical trials	24
Relationships of change in Clinical Dementia Rating (CDR) on patient outcomes and probability of progression: observational analysis	24

Plasma biomarkers for early detection of alzheimer’s disease: a cross-sectional study in a Japanese cohort	24
Association of midlife body-weight variability and cycles with earlier dementia onset: a nationwide cohort study	24
Adiponectin deficiency drives cerebrovascular dysfunction and synergizes with amyloid-β to exacerbate alzheimer’s pathology	24
REM sleep is associated with the volume of the cholinergic basal forebrain in aMCI individuals	24
Prediction of conversion from mild cognitive impairment to Alzheimer’s disease and simultaneous feature selection and grouping using Medicaid claim data	24
Comparison of plasma and neuroimaging biomarkers to predict cognitive decline in non-demented memory clinic patients	24
Association of Alzheimer’s disease polygenic risk scores with amyloid accumulation in cognitively intact older adults	24
Impact of appendicular skeletal muscle mass on Alzheimer’s disease in relation to age and comorbidities: an 8-year longitudinal follow-up study of a nationwide cohort	24
Communication about diagnosis, prognosis, and prevention in the memory clinic: perspectives of European memory clinic professionals	24
Correction: Reduction of NgR in perforant path decreases amyloid-β peptide production and ameliorates synaptic and cognitive deficits in APP/PS1 mice	23
First-in-human study of neuron regenerative therapy NNI-362 to evaluate the safety, pharmacokinetics, and pharmacodynamics in healthy aged population	23
A polygenic risk score for Alzheimer’s disease constructed using APOE-region variants has stronger association than APOE alleles with mild cognitive impairment in Hispanic/Latino adults in the U.S.	23
Multi-omics analysis reveals the key factors involved in the severity of the Alzheimer’s disease	23
Neuronal transcriptome, tau and synapse loss in Alzheimer’s knock-in mice require prion protein	23
Methodological quality of systematic reviews on treatments for Alzheimer’s disease: a cross-sectional study	23
How healthy participants value additional diagnostic testing with amyloid-PET in patients diagnosed with mild cognitive impairment — a bidding game experiment	23
The impact of subthreshold levels of amyloid deposition on conversion to dementia in patients with amyloid-negative amnestic mild cognitive impairment	23
Neurodegenerative biomarkers in different chambers of the eye relative to plasma: an agreement validation study	23
Neuron-derived extracellular vesicles in blood reveal effects of exercise in Alzheimer’s disease	23
Axonal degeneration and amyloid pathology predict cognitive decline beyond cortical atrophy	22
Association between self-reported poor oral health and subjective cognitive decline: a cross-sectional analysis of US survey data	22
Lipidomics profiling reveals distinct patterns of plasma sphingolipid alterations in Alzheimer’s disease and vascular dementia	22
Development and validation of a novel panel of CSF biomarkers for Alzheimer’s disease	22
The role of type 2 diabetes in the association between habitual glucosamine use and dementia: a prospective cohort study	22
Altered basal forebrain function during whole-brain network activity at pre- and early-plaque stages of Alzheimer’s disease in TgF344-AD rats	22
Alteration of medial temporal lobe metabolism related to Alzheimer’s disease and dementia with lewy bodies	22
Long-term retrieval performance is associated with CA1 hippocampal volume in older adults and individuals at risk for dementia	22
Circular RNA APP contributes to Alzheimer’s disease pathogenesis by modulating microglial polarization via miR-1906/CLIC1 axis	22
Reference intervals for plasma amyloid-β, total tau, and phosphorylated tau181 in healthy elderly Chinese individuals without cognitive impairment	22
Purpose in life promotes resilience to age-related brain burden in middle-aged adults	22
Speech digital biomarker combined with fluid biomarkers predict cognitive impairment through machine learning	22
Sex differences in Alzheimer’s disease CSF biomarkers and their association with Aβ pathology on PET in cognitively unimpaired individuals	22
When Alzheimer’s pathology meets cardiometabolic risk: intrinsic subcortical–cortical connectivity signatures of retroactive interference in aging	22
Fibre density and cross-section associate with hallmark pathology in early Alzheimer’s disease	21
The effects of a moderate physical activity intervention on physical fitness and cognition in healthy elderly with low levels of physical activity: a randomized controlled trial	21
Double cutoff strategies for plasma pTau217 to predict Tau PET positivity across multiple assay platforms: Tau-enriched and Tau-scarce cohorts for cost-effective clinical use	21
Correction: Impact of cumulative exposure to anticholinergic and sedative drugs on cognition in older adults: a memory clinic cohort study	21
An accessible and efficient mobile eye-tracking application for community-based cognitive impairment screening in China	21
The relationship between retinal layers and brain areas in asymptomatic first-degree relatives of sporadic forms of Alzheimer’s disease: an exploratory analysis	21
Molecular insights into sex-specific metabolic alterations in Alzheimer’s mouse brain using multi-omics approach	21
Altered temporal dynamics of prefrontal ERP responses reflecting neural adaptation in patients with amnestic mild cognitive impairment	21
Cerebrospinal fluid α-synuclein adds the risk of cognitive decline and is associated with tau pathology among non-demented older adults	21
Genome-wide association study and polygenic risk scores of retinal thickness across the cognitive continuum: data from the NORFACE cohort	21
Optimizing midlife metabolic syndrome thresholds for dementia: a prospective study of two UK population-based cohorts	21
Exploring the potential of fully automated LUMIPULSE G plasma assays for detecting Alzheimer’s disease pathology	21
Alzheimer’s polygenic risk scores, APOE, Alzheimer’s disease risk, and dementia-related blood biomarker levels in a population-based cohort study followed over 17 years	21
The presence of circulating human apolipoprotein J reduces the occurrence of cerebral microbleeds in a transgenic mouse model with cerebral amyloid angiopathy	21
Correction: Photobiomodulation mitigates blood–brain barrier disruption in APP/PS1 mouse model of Alzheimer’s disease by activating the AMPK pathway	21
Small vessel cerebrovascular disease is associated with cognition in prospective Alzheimer’s clinical trial participants	21
Combining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly	20
Increased levels of GFAP and purinergic P2X7 receptor in Alzheimer’s disease brain are associated with Aβ, tau pathologies and synaptic loss	20
Correction: Short‑term variability of Alzheimer’s disease plasma biomarkers in a mixed memory clinic cohort	20
Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer’s disease, positive for plasma p-tau217	20
The course of primary progressive aphasia diagnosis: a cross-sectional study	20
Diabetes status, duration, and risk of dementia among ischemic stroke patients	20
Restless leg syndrome and risk of all-cause dementia: a nationwide retrospective cohort study	20
Efficacy and safety of N-acetylcysteine in patients with mild cognitive impairment undergoing exercise-based cardiac rehabilitation program: a randomized controlled trial	20
Correction: Abdominal obesity and the risk of young-onset dementia in women: a nationwide cohort study	20
Tau levels are higher in objective subtle cognitive decline but not subjective memory complaint	20
Novel CSF β-synuclein-specific assays signal early synaptic degeneration in Alzheimer’s disease	20
Anticipatory reaching motor behavior characterizes patients within the Alzheimer’s disease continuum in a virtual reality environment	20
Correction: Italian adaptation of the Uniform Data Set Neuropsychological Test Battery (I‑UDSNB 1.0): development and normative data	20
Diagnostic value of serum versus plasma phospho-tau for Alzheimer’s disease	20
Frontotemporal structure preservation underlies the protective effect of lifetime intellectual cognitive reserve on cognition in the elderly	20
Exploring sex differences in Alzheimer’s disease: a comprehensive analysis of a large patient cohort from a memory unit	20
Secular trends in incidence, survival, and health status at diagnosis of dementia in Sweden, 2007–2022	19
Rationale and design of the BeyeOMARKER study: prospective evaluation of blood- and eye-based biomarkers for early detection of Alzheimer’s disease pathology in the eye clinic	19
Soluble SorLA in CSF, a novel biomarker to explore disrupted trafficking of SorLA protein in Alzheimer disease	19
Diagnostic performance of automated plasma amyloid-β assays combined with pre-analytical immunoprecipitation	19
Longitudinal validation of cognitive reserve proxy measures: a cohort study in a rural Chinese community	19
Recruitment across two decades of NIH-funded Alzheimer’s disease clinical trials	19
Hampered AMPK-ULK1 cascade in Alzheimer’s disease (AD) instigates mitochondria dysfunctions and AD-related alterations which are alleviated by metformin	19
Human in vivo evidence of associations between herpes simplex virus and cerebral amyloid-beta load in normal aging	19
Insomnia, early and late rising are associated with small hippocampal volume and large white matter hyperintensity burden	19
Sex and APOE ε4 genotype modify risk factor associations with cerebral amyloid angiopathy: a multi-cohort autopsy study	19
Neurobiological correlates of Mild Behavioral Impairment: a systematic review and meta-analysis	19
Clinical implications of head trauma in frontotemporal dementia and primary progressive aphasia	19
NeuroEPO plus (NeuralCIM®) in mild-to-moderate Alzheimer’s clinical syndrome: the ATHENEA randomized clinical trial	19
Deletion of Abi3/Gngt2 influences age-progressive amyloid β and tau pathologies in distinctive ways	19
Plasma amyloid-beta oligomer is related to subjective cognitive decline and brain amyloid status	19
Explaining the association between social and lifestyle factors and cognitive functions: a pathway analysis in the Memento cohort	18
Biophysical models applied to dementia patients reveal links between geographical origin, gender, disease duration, and loss of neural inhibition	18
Development and validation of a novel predictive model for dementia risk in middle-aged and elderly depression individuals: a large and longitudinal machine learning cohort study	18
The effects of imaging markers on clinical trajectory in cerebral amyloid angiopathy: a longitudinal study in a memory clinic	18
The relationship of insulin resistance and diabetes to tau PET SUVR in middle-aged to older adults	18
Intermittent hypoxia training enhances Aβ endocytosis by plaque associated microglia via VPS35-dependent TREM2 recycling in murine Alzheimer’s disease	18
Classification of Alzheimer’s disease in a mixed clinical cohort using biofluid Raman spectroscopy	18
Associations of computer gaming with incident dementia, cognitive functions, and brain structure: a prospective cohort study and Mendelian randomization analysis	18
Network dynamics-based subtyping of Alzheimer’s disease with microglial genetic risk factors	18
Neuroimaging of tissue microstructure as a marker of neurodegeneration in the AT(N) framework: defining abnormal neurodegeneration and improving prediction of clinical status	18
N, N-Dimethyltryptamine, a natural hallucinogen, ameliorates Alzheimer’s disease by restoring neuronal Sigma-1 receptor-mediated endoplasmic reticulum-mitochondria crosstalk	18
Selective reduction of ADAM10 in brain and cerebrospinal fluid of Alzheimer’s disease patients	18
Prevalence of treated patients with Alzheimer’s disease: current trends and COVID-19 impact	18
Retinal mid-peripheral capillary free zones are enlarged in cognitively unimpaired older adults at high risk for Alzheimer’s disease	18
Intracerebral hemorrhage following mild ARIA-H in an APOE ε2 carrier receiving lecanemab	18